The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with greatest potential.

The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.

The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.

Despite initial slow sales, the firm's CEO cited areas for Leqembi's growth and ambitions for an antisense oligonucleotide ...

The firm will use the funds to establish a commercial lab and continue advancing its AI- and sequencing-based platform for personalizing cancer treatment.

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

The firm is using immunohistochemistry to gauge biomarker expression before enrolling patients in a trial of its CLDN 18.2-directed antibody-drug conjugate.

In a pooled analysis from two trials, Dato-DXd has shown promise as a treatment for advanced EGFR-mutated NSCLC.